Premium
Bioinformatics Prediction and In Vitro Analysis Revealed That mi R ‐17 Targets Cyclin D 1 m RNA in Triple Negative Breast Cancer Cells
Author(s) -
Karami Fariba,
MohammadiYeganeh Samira,
Abedi Nairi,
Koochaki Ameneh,
Kia Vahid,
Paryan Mahdi
Publication year - 2016
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12671
Subject(s) - triple negative breast cancer , breast cancer , cyclin d1 , cancer research , estrogen receptor , cancer , biomarker , gene expression , biology , targeted therapy , messenger rna , microrna , gene , microbiology and biotechnology , cell cycle , genetics
Breast cancer is one of the most prevalent malignancies among women worldwide. Triple negative breast cancer ( TNBC ) is a type of breast cancer in which estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 ( HER ‐2) are not expressed. There is no targeted therapy for this type of cancer, and available therapies have poor therapeutic effects. Performing a preliminary research, we selected cyclin D 1 ( CCND 1 ) gene of W nt signaling pathway which is a target of mi RNA s, a promising set of biomolecules in diagnosis and treatment of breast cancer. In this study using bioinformatic analyses, mi R ‐17 was selected as it targets the 3′ UTR of CCND 1 gene with the highest score. Luciferase assay results also confirmed the bioinformatic prediction. Decreased expression of mi R ‐17 in MDA ‐ MB ‐231 cell line was observed using q RT ‐ PCR method. After lentiviral transduction of mi R ‐17 to the target cells, gene expression analysis showed decreased expression of CCND 1 gene. We found mi R ‐17 as an attractive molecule that after intensive research can probably be used as a biomarker in TNBC .